The resulting SRH–DR5-B fusion retained high affinity to both the VEGFR2 and DR5 receptors and demonstrated increased cytotoxic activity in 3D multicellular tumor spheroids, so it can be considered a prospective candidate for concurrent antitumor and antiangiogenic therapy. Here, KDR is linked to neoplasm.